Oxybuprocaine
Based on 1 Customer Validation
Oxybuprocaine is a short-acting ester anesthetic. Oxybuprocaine binds to sodium channels and reversibly stabilizes neuronal membranes. Oxybuprocaine has cutaneous analgesic properties. Oxybuprocaine is less potent than Bupivacaine (HY-B0405) at producing central nervous system and cardiovascular toxicity. Oxybuprocaine can be used in ophthalmology and otolaryngology.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit: 99.93%
- CAS. Nr.: 99-43-4
- Formel: C17H28N2O3
- Molecular Weight:308.42
-
Speicherung:Pure form -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
-
Lösungsmittel & Löslichkeit
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
-
Membrane Transporter/Ion Channel Compound Library
HY-L011
-
FDA-Approved Drug Library
HY-L022
-
Drug Repurposing Compound Library
HY-L035
-
Anti-Cardiovascular Disease Compound Library
HY-L046
-
FDA Approved & Pharmacopeial Drug Library
HY-L066
-
Rare Diseases Drug Library
HY-L102
-
Protein-protein Interaction Inhibitor Library
HY-L109
-
Human Metabolite Library
HY-L123
-
Off-patent Drug Library
HY-L141
-
Membrane Protein-targeted Compound Library
HY-L149
-
Membrane Receptor-targeted Compound Library
HY-L150
-
Ion Channel Compound Library
HY-L166
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Drug Repurposing Compound Library Plus
HY-L035P
-
FDA-Approved Drug Library Plus
HY-L022P
-
FDA-Approved Drug Library Mini
HY-L022M
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
-
Mass Spectrometry Human Metabolite Library
HY-L215
Biologische Aktivität
Oxybuprocaine (6.67 μmol/kg/min; i.v.) hydrochloride produces slower decreases in mean arterial blood pressure and heart rate compared with Bupivacaine (HY-B0405) in Sprague-Dawley rats, and the time to induce seizure, apnea, and impending death is longer than that of Bupivacaine[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS. Nr. 99-43-4
-
Appearance Viscous Liquid
-
Molecular Weight 308.42
-
Formel C17H28N2O3
-
Color Colorless to light yellow
-
SMILES
O=C(OCCN(CC)CC)C1=CC=C(N)C(OCCCC)=C1
-
Synonyms
Benoxinate; Novesinol; Oxybucaine
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Pure form -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Lösungsmittel & Löslichkeit
DMSO : ≥ 125 mg/mL (405.29 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Reinheit & Dokumentation
-
Data Sheet (270 KB)
-
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
-
Handling Instructions (2659 KB)
Verweise
[1]. Masayuki Kohsaka, et al. Oxybuprocaine for apraxia of lid opening in Parkinson's disease: A placebo-controlled pilot trial. Mov Disord [Content Brief]
[2]. Nam SM, et al. Comparison of corneal thickness after the instillation of topical anesthetics: proparacaine versus oxybuprocaine. Cornea. 2006 Jan;25(1):51-4. [Content Brief]
[3]. Tomaciello F, et al. Resveratrol lacks protective activity against acute seizures in mouse models. Neurosci Lett. 2016 Oct 6;632:199-203. [Content Brief]
[4]. Hung CH, et al. The systemic toxicity of equipotent proxymetacaine, oxybuprocaine, and bupivacaine during continuous intravenous infusion in rats. Anesth Analg. 2010 Jan 1;110(1):238-42. [Content Brief]
[6]. Dong Z, et al. Efficacy and Safety of Oxybuprocaine Hydrochloride Gel in Alleviating Pain during Male Urethral Catheterization: A Single-Center Randomized Controlled Study. Int J Clin Pract. 2022 Sep 14;2022:5734387. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.2423 mL | 16.2117 mL | 32.4233 mL | 81.0583 mL |
| 5 mM | 0.6485 mL | 3.2423 mL | 6.4847 mL | 16.2117 mL | |
| 10 mM | 0.3242 mL | 1.6212 mL | 3.2423 mL | 8.1058 mL | |
| 15 mM | 0.2162 mL | 1.0808 mL | 2.1616 mL | 5.4039 mL | |
| 20 mM | 0.1621 mL | 0.8106 mL | 1.6212 mL | 4.0529 mL | |
| 25 mM | 0.1297 mL | 0.6485 mL | 1.2969 mL | 3.2423 mL | |
| 30 mM | 0.1081 mL | 0.5404 mL | 1.0808 mL | 2.7019 mL | |
| 40 mM | 0.0811 mL | 0.4053 mL | 0.8106 mL | 2.0265 mL | |
| 50 mM | 0.0648 mL | 0.3242 mL | 0.6485 mL | 1.6212 mL | |
| 60 mM | 0.0540 mL | 0.2702 mL | 0.5404 mL | 1.3510 mL | |
| 80 mM | 0.0405 mL | 0.2026 mL | 0.4053 mL | 1.0132 mL | |
| 100 mM | 0.0324 mL | 0.1621 mL | 0.3242 mL | 0.8106 mL |
Oxybuprocaine Related Classifications
HY-B1288A Related Classifications
Powered by Bioz